APC and neoplasm: In addition, the demonstration that experimental “toolbox” tankyrase inhibitors can inhibit oncogenic Wnt signaling in colorectal tumour cells3 has driven the discovery of additional, drug-like, tankyrase inhibitors that could be used to target tumours that have constitutively active Wnt signaling, such as those with premature truncating mutations in the APC tumour suppressor protein4.